Abstract: The present invention discloses an application of TREM2hi macrophages in preparation of drugs for treating cardiac dysfunction, and belongs to the technical field of medicine. The present invention discloses for the first time that there is a kind of macrophage subsets for high expression of a triggering receptor expressed on myeloid cells-2 in cardiac derived macrophages, which has a strong function of recognizing and reducing mitochondrial damage and plays an important role in maintaining a cardiac metabolic balance. Therefore, the TREM2hi macrophages have important application value in treatment of the cardiac dysfunction.

Abstract: A human ?-defensin 5 variant is obtained by adding amino acid residues at C-terminal of ?-defensin 5 and then being modified to link an aliphatic acid. At least one of the added amino acid residues has a free amino group, and the free amino group is modified to link an aliphatic acid with 8-24 carbon atoms. The variant is used in manufacture of an antibacterial agent and an immunomodulatory agent. Antibacterial activity is significantly enhanced by extending and modifying the C-terminal of HD-5; in particular, salt tolerance is significantly improved by extending the C-terminal of HD-5 with Lys and then being modified with myristic acid, thereby breaking the restriction of salt-sensibility of conventional antimicrobial peptides. The variant can significantly promote release of inflammatory factors from macrophages and thus can be applied in manufacture of immunomodulatory agent.

Abstract: A human ?-defensin 5 variant is obtained by adding amino acid residues at C-terminal of ?-defensin 5 and then being modified to link an aliphatic acid. At least one of the added amino acid residues has a free amino group, and the free amino group is modified to link an aliphatic acid with 8-24 carbon atoms. The variant is used in manufacture of an antibacterial agent and an immunomodulatory agent. Antibacterial activity is significantly enhanced by extending and modifying the C-terminal of HD-5; in particular, salt tolerance is significantly improved by extending the C-terminal of HD-5 with Lys and then being modified with myristic acid, thereby breaking the restriction of salt-sensibility of conventional antimicrobial peptides. The variant can significantly promote release of inflammatory factors from macrophages and thus can be applied in manufacture of immunomodulatory agent.

Abstract: An integrated capacitor can be fabricated with both electrodes formed by trenches for low resistance. According to one embodiment, the capacitor can comprise a first trench electrode, one or more dielectric layers, and a second trench electrode. The first trench electrode and the second trench electrode can be fabricated in different trenches to improve capacitance density and resistance of the integrated capacitor.

Abstract: An integrated capacitor can be fabricated with both electrodes formed by trenches for low resistance. According to one embodiment, the capacitor can comprise a first trench electrode, one or more dielectric layers, and a second trench electrode. The first trench electrode and the second trench electrode can be fabricated in different trenches to improve capacitance density and resistance of the integrated capacitor.

Abstract: Methods and apparatus described herein are associated with integrated magnetic induction devices. A magnetic induction device can include a groove formed in a substrate, a magnetic core included in the groove and surrounded by a conductive winding that is adjacent to portion(s) of the substrate, and respective insulation layers included between the substrate and the conductive winding and between the magnetic core and the conductive winding. An inductor can further include conductive vias formed in the substrate and connected to respective portions of the conductive winding. Further, a transformer can include a groove formed in a substrate, a closed-loop/gapped magnetic core included in the groove and surrounded by first and second conductive windings that are adjacent to respective portions of the substrate, and respective insulation layers formed between the substrate and the first and second conductive windings, and between the closed-loop/gapped magnetic core and the first and second conductive windings.

Abstract: Methods and apparatus described herein are associated with integrated magnetic induction devices. A magnetic induction device can include a groove formed in a substrate, a magnetic core included in the groove and surrounded by a conductive winding that is adjacent to portion(s) of the substrate, and respective insulation layers included between the substrate and the conductive winding and between the magnetic core and the conductive winding. An inductor can further include conductive vias formed in the substrate and connected to respective portions of the conductive winding. Further, a transformer can include a groove formed in a substrate, a closed-loop/gapped magnetic core included in the groove and surrounded by first and second conductive windings that are adjacent to respective portions of the substrate, and respective insulation layers formed between the substrate and the first and second conductive windings, and between the closed-loop/gapped magnetic core and the first and second conductive windings.

Abstract: The present invention provides compositions and methods for affinity separation of targets from mixtures. In particular, disclosed are avian IgY antibodies coupled to solid supports and their methods of use.

Abstract: The present invention provides compositions and methods for immunoaffinity separation of targets from mixtures for enrichment, identification, quantification, and analysis. In particular, disclosed are avian IgY antibodies coupled to solid supports and their methods of use. Further disclosed are systems and methods for fractionating or enrichment a mixture of biological materials in an automated multiplex and high-throughput platform or system.

Abstract: Affinity separation compositions and methods are disclosed for separating targets from complex mixtures. Affinity reagents are bound to a solid support oriented in a manner to facilitate the activity of the affinity reagents which are capable of binding specific targets by affinity recognition. Affinity reagents include IgY antibodies, proteins, peptides, nucleotides and polymers. Targets include proteins, protein-protein complexes, protein-nucleotide complexes, nucleotides, cells and subcellular organelles.

Abstract: This invention encompasses a composition for killing target cells, such as tumor cells. The composition comprises a first and a second adenoviral vector that have complementary function and are mutually dependent on each other for replication in a target cell. One of said adenoviral vectors has a target cell-activated promoter or a functional deletion that controls and limits propagation of the adenoviral vectors in the target cells which directly or indirectly kills the target cells. One of the adenoviral vectors comprises a gene encoding a protein which is expressed in the target cells and can induce anticancer immune responses. The target cells may be hepatoma, breast cancer, melanoma, colon cancer, or prostate cancer cells, for example. The vectors of this invention may also be utilized to treat other diseases such as restenosis, in which case the target cell may be a vascular smooth muscle cell, for example.

Abstract: This invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including, but not limited to, gene vaccination, gene transfer, gene therapy, and the like. More specifically, this invention is related to the Ad vectors that carry the minimal cis-element of the Ad genome (minimal Ad vector) and are capable of delivering about 36 kb to about 38 kb of heterologous DNA. The generation and propagation of the minimal Ad vectors require trans-complementation of a packaging-attenuated and replication-defective helper Ad (helper) in an Ad helper cell line.

Abstract: This invention encompasses a composition for killing target cells, such as tumor cells. The composition comprises a first and a second adenoviral vector that have complementary function and are mutually dependent on each other for replication in a target cell. One of said adenoviral vectors has a target cell-activated promoter or a functional deletion that controls and limits propagation of the adenoviral vectors in the target cells which directly or indirectly kills the target cells. One of the adenoviral vectors comprises a gene encoding a protein which is expressed in the target cells and can induce anticancer immune responses. The target cells may be hepatoma, breast cancer, melanoma, colon cancer, or prostate cancer cells, for example. The vectors of this invention may also be utilized to treat other diseases such as restenosis, in which case the target cell may be a vascular smooth muscle cell, for example.